It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look to be letting up anytime soon. But, according to a new report from Evaluate, obesity products are set to take over many familiar stalwarts on the world’s top-selling drugs list by the end of the decade.
Fierce Pharma
Internet News
New York, New York 90,363 followers
Pharma’s go-to destination for news & trends shaping approved drugs.
About us
Fierce Pharma is the go-to destination for the news and trends shaping the industry. Our focus daily is on news about approved drugs and every aspect of pharma’s operations as well as the people who move pharma forward. Our coverage also feeds longer-form content, podcasts and events. In staying on top of the news, our journalists have developed a loyal audience. Critically, we explain the news—often complicated technology or business maneuvers—and put it in context that brings it home for our readers and listeners in their work lives. Delivering news, revealing insights straight to your inboxes: https://fiercepharma.questexinfo.com/loading.do?omedasite=Pharma_full. Our family of publications includes Fierce Pharma, Fierce Pharma PM Tracker, Fierce Pharma Marketing, Fierce Manufacturing, Fierce Drug Delivery and Fierce Life Sciences Weekly Digest. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Biotech news you can’t miss: https://www.linkedin.com/showcase/fierce-biotech For Healthcare news you can’t miss: https://www.linkedin.com/showcase/fierce-healthcare
- Industry
- Internet News
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2006
Locations
-
Primary
685 3rd Ave
21st Floor
New York, New York 10017, US
Employees at Fierce Pharma
Updates
-
Novo Nordisk has won approval in Europe, Canada and Japan for its once-weekly insulin icodec. But the FDA has rejected it for manufacturing issues.
Citing manufacturing issue, FDA rejects Novo Nordisk's once-weekly insulin
fiercepharma.com
-
While much of the attention on Novo Nordisk these days revolves around the company’s wildly popular GLP-1 drugs Ozempic and Wegovy, insulin remains a critical backbone for the drugmaker.
Amid GLP-1 boom, Novo Nordisk strikes up insulin partnership in Indonesia
fiercepharma.com
-
Bayer’s massive reorganization championed by CEO Bill Anderson is bringing major changes to the German company’s pharma commercial team, shaking up its structure, personnel and operations.
Bayer to largely complete layoffs within pharma commercial team in 2024, exec says
fiercepharma.com
-
Is Eli Lilly and Company's Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? While a head-to-head trial pitting the two treatments remains ongoing, new evidence shows that Lilly’s tirzepatide may be the superior weight loss product.
Lilly's Mounjaro triggers more weight loss than Novo Nordisk's Ozempic: study
fiercepharma.com
-
It took many years, but Johnson & Johnson’s tuberculosis med Sirturo can finally claim full approvals in the U.S. and Europe following initial conditional
J&J's tuberculosis med Sirturo lands full US, EU approvals after more than a decade on the market
fiercepharma.com
-
After a drawn-out litigation process, Merck seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax.
Merck puts 1,000-plus Zostavax lawsuits to bed after plaintiffs file for dismissal
fiercepharma.com
-
As Korean CDMO giant Samsung Biologics continues to ink production pacts around the globe, the company has added another billion-dollar feather to its cap.
High-flying Samsung Biologics inks $1B production pact with unnamed US pharma
fiercepharma.com
-
After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy—and a competitor to Eisai and Biogen’s Leqembi—a full approval.
Game on: Lilly's Alzheimer's drug Kisunla, a challenger to Biogen and Eisai's Leqembi, gains full FDA nod
fiercepharma.com
-
In a new USA Today op-ed piece, President Joe Biden and Sen. Bernie Sanders blasted Novo Nordisk for "charging the American people unconscionably high prices" for its popular GLP-1 medicines Ozempic and Wegovy.
Biden joins Sanders' campaign targeting Novo Nordisk, Eli Lilly's diabetes and obesity drug prices
fiercepharma.com